Sanofi Expands its 2018 Collaboration with Translate Bio to Develop mRNA Vaccines Against Infectious Diseases

 Sanofi Expands its 2018 Collaboration with Translate Bio to Develop mRNA Vaccines Against Infectious Diseases

Sanofi Expands its 2018 Collaboration with Translate Bio to Develop mRNA Vaccines Against Infectious Diseases

Shots:

  • Translate Bio to receive $425M up front consisting $300M in cash and $125M as equity investment at $25.59/ share representing a 50% premium to the 20-day moving average share price prior to signing. The company will receive ~$1.9B as milestones, including $450M milestones under the 2018 agreement and expects $360M in next few years for its COVID-19 vaccine
  • Moreover, Translate Bio will receive royalties on global sales of developed vaccines. Sanofi will get an exclusive worldwide right for infectious disease vaccines and will be responsible for the cost during the collaboration and utilizes Translate Bio’s technology
  • The companies are advancing an mRNA vaccine against influenza through preclinical studies with clinical trial initiation anticipated in mid-year 2021 whereas the companies will initiate the first-in-human clinical trial of its COVID-19 vaccine in Q4’20

Click here to read full press release/ article | Ref: Sanofi | Image: Life Science IP Review

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post